Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Latest From Sanofi

Deal Watch: Takeda Signs Broad Cancer Collaboration With Nektar

Takeda will pair five cancer candidates with different mechanisms of action with Nektar's NKTR-214 and Merck follows up its Phase III disappointment verubecestat by licensing a preclinical Alzheimer's drug from Teijen.

Deals M & A

Disappointing Bydureon EXSCEL Outcomes Data May Raise Stakes For Victoza

AstraZeneca's EXSCEL study could have created confidence in a GLP-1 class-wide outcomes benefit, but instead it has raised questions about whether differences in trial results boil down to trial design.

Research & Development Metabolic Disorders

Sanofi/Regeneron's Kevzara Priced To Break Into A Crowded Market

The partners are looking to create a compelling value proposition for the interleukin-6 inhibitor, approved by FDA to treat moderate to severe RA, by pricing it below the market-leading anti-TNFs.

Immune Disorders Pricing Strategies

Scrip Asks… Is The Biosimilar Cost-Saving Theory Sustainable?

Scrip asks industry whether the promise of biosimilars producing substantial cost-savings is a sustainable model to help healthcare systems afford the next wave of expensive biologics. Drug developers and trade associations comment on the caveats still in play when it comes to biosimilars, cost-cutting and market access.

Biosimilars Market Access
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register